Nexavar
Nexavar Official FDA information, side effects and uses.
Posted by Nexavar (Nexavar) on Fri, 24 Aug 2007 00:25:25 +0000
Bayer and Onyxs Nexavar has been granted priority for hepatocellular carcinoma from the FDA and a final decision regarding its approval is now expected in the next few months. The drug has been shown to significantly extend overall survival in previously untreated patients, a population with a high unmet need, ensuring adoption as the standard of care for this patient group.
Nexavar Granted FDA Priority Review For Treatment Of Liver Cancer (Medical News Today)
Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. [click link for full ...
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer (The San Francisco Examiner)
WAYNE, N.J. ( Map ) - Bayer HealthCare Pharmaceuticals (NYSE: BAY ) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that the supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. ...
Bayer, Onyx say FDA grants Nexavar liver cancer treatment priority review (Sharewatch)
LEVERKUSEN, Germany (Thomson Financial) - Bayer AG and US company Onyx Pharmaceuticals Inc said their application for Nexavar to be approved as a treatment of hepatocellular carcinoma, the most common form of liver cancer, has been accepted for review and granted priority review status by the US Food and Drug Administration.
Onyx, Bayer Drug Gets Priority Review (AP via Yahoo! Finance)
Bayer AG and Onyx Pharmaceuticals Inc. said Monday the Food and Drug Administration gave priority review for the application of its drug Nexavar as a liver cancer treatment.
